Home
Radiology Guides Anatomy Physio & Path Medicine Physics Contact
STROKE-ANTIPLATELET THERAPY

Neurology

STROKE-ANTIPLATELET THERAPY

1. For patients with non-cardioembolic ischemic stroke or TIA, the risk of recurrent stroke and other events is reduced with antiplatelet agents: Aspirin, Dipyridamole, Clopidogrel.

2. The oral administration of aspirin 325 mg within 24 to 48 hours after an ischemic stroke onset is recommended for secondary stroke prevention.

3. Antiplatelet medications have been shown to be beneficial in the secondary stroke prevention of presumed arterial origin.

4. Aspirin plus extended-release dipyridamole (Aggrenox) has demonstrated to have additive benefit over monotherapy with each agent.

5. The combination of clopidogrel and aspirin has not been shown to provide any significant additional protection against recurrent ischemic stroke over each agent individually (Creager, 1998).

6. Moreover, the combination increases the risk of life-threatening or major bleeding side effects (MATCH Study; Diener et al., 2004).


Avatar
REFERENCES

1. Wilkinson, I. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press.
2. Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
3. Image: no reference available.

Ⓒ A. Manickam 2018

+ Home